Upload Avatar (500 x 500)
Shu Shaokun
Basic Medical Sciences
Peking University
Beijing
Language: Chinese, English
Epigenetics
Therapy
Tumor
Microenvironment
Drug
High-Throughput
Gene
Editing
Crispr
Screening
Areas of Focus
- Oncological Epigenetics
- Targeted Therapy
- Tumor Microenvironment
- Combination Drug Therapy
- High-throughput Gene Editing Screening (CRISPR Screen)
Work Experience
- 2003.8 – 2005.8: Chinese Academy of Sciences, Research Assistant
- 2011.1 – 2011.8: University of South Florida, Postdoctoral Fellow
- 2011.8 – 2019.8: Dana-Farber Cancer Institute, Harvard Medical School, Postdoctoral Fellow/Lecturer
- 2019.9 – present: Peking University Cancer Hospital & Institute, Researcher
Academic Background & Achievements
- 1999-2003 Bachelor in Bioengineering, Beijing Institute of Technology
- 2005-2010 PhD in Molecular Oncology, University of South Florida
Publications
- Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer, Shu S, Wu HJ, Ge JY, Zeid R, Harris IS, Jovanović B, Murphy K, Wang B, Wucherpfennig KW, Qi J, Liu XS, Long H, Brown M, Carroll JS, Brugge JS, Bradner J, Michor F, Polyak K, 2020
- Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer, Ge JY, Shu S, Kwon M, Jovanović B, Murphy K, Gulvady A, Fassl A, Trinh A, Kuang Y, Heavey GA, Luoma A, Paweletz C, Thorner AR, Wucherpfennig KW, Qi J, Brown M, Sicinski P, McDonald TO, Pellman D, Michor F, Polyak K, 2020
- Response and resistance to BET bromodomain inhibitors in triple negative breast cancer, Shu S, Lin CY, He HH, Witwicki RM, Tabassum DP, Roberts JM, Janiszewska M, Huh SJ, Liang Y, Ryan J, Doherty E, Mohammed H, Guo H, Stover DG, Ekram MB, Peluffo G, Brown J, D'Santos C, Krop IE, Dillon D, McKeown M, Ott C, Qi J, Ni M, Rao PK, Duarte M, Wu SY, Chiang CM, Anders L, Young RA, Winer EP, Letai A, Barry WT, Carroll JS, Long HW, Brown M, Liu XS, Meyer CA, Bradner JE, Polyak K, 2016
- BET Bromodomain Proteins as Cancer Therapeutic Targets, Shu S, Polyak K, 2016
- Subclonal cooperation drives metastasis by modulating local and systemic immune microenvironments, Janiszewska M, Tabassum DP, Castaño Z, Cristea S, Yamamoto KN, Kingston NL, Murphy KC, Shu S, Harper NW, Del Alcazar CG, Alečković M, Ekram MB, Cohen O, Kwak M, Qin Y, Laszewski T, Luoma A, Marusyk A, Wucherpfennig KW, Wagle N, Fan R, Michor F, McAllister SS, Polyak K, 2019
- TRPS1 Is a Lineage-Specific Transcriptional Dependency in Breast Cancer, Witwicki RM, Ekram MB, Qiu X, Janiszewska M, Shu S, Kwon M, Trinh A, Frias E, Ramadan N, Hoffman G, Yu K, Xie Y, McAllister G, McDonald R, Golji J, Schlabach M, deWeck A, Keen N, Chan HM, Ruddy D, Rejtar T, Sovath S, Silver S, Sellers WR, Jagani Z, Hogarty MD, Roberts C, Brown M, Stegmaier K, Long H, Shivdasani RA, Pellman D, Polyak K, 2018
- Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes, Marusyk A, Tabassum DP, Janiszewska M, Place AE, Trinh A, Rozhok AI, Pyne S, Guerriero JL, Shu S, Ekram M, Ishkin A, Cahill DP, Nikolsky Y, Chan TA, Rimawi MF, Hilsenbeck S, Schiff R, Osborne KC, Letai A, Polyak K, 2016
Awards
- 2017: Jon Shevell Young Scientist Scholarship, Keyston Epigenetics symposium, Seattle
- 2016: Jon Shevell Young Scientist Scholarship, Cold Spring Harbor Annual Meeting, New York
- 2015: AACR Breast Cancer training award, AACR Breast Cancer Annual Meeting, Seattle
- 2010: Travel award and oral presentation, American Association for Cancer Research, Mini-symposium
